T riamcinoloneacetonide(TA)isworldwideavailable therapeuticagentthatiscommonlyusedthroughout medicine.TAremainsasafeandimportantophthalmic therapeuticagentevenaftertheadventofangiogenesis inhibitors [1] [2] . Intravitreal TA effectivenesshasbeen demonstratedeitheraloneorcombinedwithothertreatment options [3] [4] .SeveralcommerciallyavailableTAformulations arebeingusedforintravitrealinjection.TAformulationsvary inpHvalue,particlesize,crystallinity,solubility,dissolution, andflowkineticsbothduringandafterintravitrealinjection [5] [6] [7] [8] [9] . Allofwhichareimportantfortheclinicalunderstandingof thetherapeuticeffectsandsafetyprofileoftheTA preparationbeingused. Triesence(AlconPharmaceuticals,Ft.Worth,TX,USA)isa FoodandDrugAdministration(FDA)approvedpreservativefreeTAformulation.Triesenceusehasincreasedmainlydue toconcernoverpotentialtoxicityofTAformulationsthat haveapreservative( Kenalog) [10] [11] . [12] [13] [14] .
Variouspreservative-freeTApreparations(
Triesence, AlconLaboratories,Inc.;Trivaris,Allergan,Inc.)havebeen developedduetoconcernsoverretinaltoxicityfromthe preservativeandbactericidalagentbenzylalcohol [10] [11] . Triesenceusehasincreasedsignificantlybecauseitisthe onlyFDAapprovedpreservative-freeTAcommercially available. ArecentstudyperformedattheBascomPalmerEye Institute,Miami,FLUSAshowedthatTriesencehas differentflowratesfromTAwithbenzylalcohol [6] .Triesence hasalsodemonstratedasignificantlyslowerdissolution profileandlowerfreedruglevelinthevitreousthanTAwith benzylalcohol [5] .Theseresultssuggestthatintravitreal Triesencemayprovidealongertherapeuticdurationandless steroid-relatedcomplications,suchascataractandIOP elevation,whencomparedtoanequivalentintravitreal injectionofTAwithbenzylalcohol,becausethese complicationsarefreeTAlevel-dependent [5] .Retinal cytotoxicityofTAisalsocrystalsizedependent,withlarger aggregatesbeingmorecytotoxic [9] .TAwithbenzylalcohol hasthelargestcytotoxicityandcrystalaggregates [9] .These studiessuggestthatdifferentTAformulationshavedifferent safetyandefficacyprofiles. Previousreportsonacuteinfectiousendophthalmitishave beenaconcernforophthalmologistsusingintravitrealTA [15] [16] . Noninfectiousendophthalmitishasalsobeenreportedwith multipleTAformulationsincludingTriesence [17] .Inour study, endophthalmitiswasnotpresent.Intraocular inflammation,vitreousopacification,andsynechiainthe absenceofanglerubeosiswerenotidentified. Previousstudieshavealsoreportedtheannualincidenceof severeIOPrise(definedasneedinglaserorfiltratingsurgery) between3.6and9.5per1000TAinjections [18] .However, dataregardingTriesenceIOPriseremainsscarce.Nopatient underwentlaserorfiltratingsurgeryinthestudy.IOPshowed nostatisticallysignificantvariationunderourtreatment protocol.IOPstabilitymightberelatedtoslowerdissolution profileandlowerfreedruglevel [5] . Multiplestudieshavereportedbest-correctedvisualacuity improvementsaftertreatmentwithintravitrealTAaloneorin combinationformacularedema [19] [20] . 
